News & Updates
Filter by Specialty:

NATALEE update: Ribociclib + NSAI well tolerated
12 Jul 2024
byElvira Manzano
Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).
NATALEE update: Ribociclib + NSAI well tolerated
12 Jul 2024
Mutations affect efficacy of avelumab in advanced endometrial cancer
09 Jul 2024
Avelumab immunotherapy may perform poorly in advanced endometrial cancer (EC) patients with TP53 mutation but has positive effects in those with mutations of PTEN and ARID1A, suggest the results of the MITO END-3 trial.
Mutations affect efficacy of avelumab in advanced endometrial cancer
09 Jul 2024
Organic pollutants found in Mediterranean diet up GDM risk
01 Jul 2024
byStephen Padilla
Adherence to a healthy dietary pattern, such as the Mediterranean diet (MedDiet), may reduce the risk of gestational diabetes mellitus (GDM) but appears to increase exposure to harmful chemicals, according to a Singapore study presented at ADA 2024.